Cambridge Healthtech Institute’s 5th Annual

Improving Immunotherapy Efficacy and Safety

Engineering the Next Generation of Immunotherapies

May 4-5, 2020

Cambridge Healthtech Institute’s 5th Annual Improving Immunotherapy Efficacy and Safety conference focuses on the latest innovations, science, novel targets, and modalities being adopted to improve immunotherapy efficacy and safety. Topics include: new approaches to immunity, the tumor microenvironment, novel IO targets and engineering strategies, emerging modalities, such as NK Cells and Gamma Deltas, immune tolerance, TREGs, plus effective strategies to mitigate toxicity. Examples will come from the world of checkpoint inhibitors, adoptive T cell therapy, combinations, cancer vaccines, oncolytic viruses, and novel immunotherapy approaches.

Preliminary Agenda


Modulation of Tumor Microenvironment to Enhance Response to Immunotherapy

Allison Betof Warner, MD, PhD, Assistant Attending Physician, Melanoma Service, Memorial Sloan Kettering Cancer Center

Development of the Next Generation of Cancer Vaccines: Targeting Tumor Neoantigens

Karin Jooss, PhD, CSO, Gritstone Oncology, Inc.

Multiplexed Activation of Endogenous Genes by CRISPRa Elicits Potent Antitumor Immunity

Sidi Chen, PhD, Associate Professor, Genetics, Yale School of Medicine


Controlling CAR T Efficacy and Safety

Travis S. Young, PhD, Vice President, Biologics, Scripps

New Directions to Enhance CAR T Cell Safety

Saad J. Kenderian, PhD, Assistant Professor, Medicine and Oncology, Mayo Clinic College of Medicine

CAR T Cells for T-Cell Malignancies

Maksim Mamonkin, PhD, Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine


Talk Title to be Announced

Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota

Cord-Blood-Derived NK Cells

Conrad Russel Cruz, PhD, Director, Translational Research Laboratories, Center for Emerging Technologies in Immune Cell Therapy, Children’s National Hospital

Genetically Engineered NK Cell Lines for Treatment of Cancer and Viral Infections

Hans Klingemann, MD, PhD, Vice President, Research and Development, NantKwest, Inc.

Simultaneous Delivery of High-Dose Chemotherapy and Gene-Modified, Chemotherapy-Resistant Gamma/Delta T Cells Improve Outcomes in Primary Glioblastoma

Lawrence Lamb, PhD, CSO, Incysus


Developments in Gamma Delta

Daniel Olive, PhD, Scientific Advisor, Imcheck Therapeutics

CAR T Cells for Allotransplantation

James Riley, PhD, Associate Professor, Microbiology, University of Pennsylvania

Engineering Novel-Targeted Cell Therapies for the Treatment of Immune Disorders

Anthony Conway, PhD, Senior Manager, Cell Therapy, Sangamo

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Sponsor updated

View By: